Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

NCT05611229 · clinicaltrials.gov ↗

COMPLETED

Status

1975

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: Nivolumab
DRUG: Pembrolizumab
COMBINATION_PRODUCT: Dabrafenib+Trametinib
COMBINATION_PRODUCT: Ipilimumab+Nivolumab
COMBINATION_PRODUCT: Vemurafenib+Cobimetinib
COMBINATION_PRODUCT: Encorafenib+Binimetinib

Sponsor

Novartis Pharmaceuticals